Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Teva CEO Steps Down While An Integration Hangs In The Balance

Feb 08 2017

• By Jessica Merrill

Clouds-Lightning-Storm_1200x675

Related Content

Teva Director Vigodman’s Name Floated As New CEO

Jan 02 2014

Teva CEO Vigodman Reveals A First Glimpse At His Strategy

May 01 2014

Copaxone 40mg Generic At-Risk Launch Anticipated As Soon As February

Feb 01 2017

Teva Hits Pause On Business Development, Even As Some Deals Stumble

Nov 15 2016

Regeneron’s Fasinumab Brings Second Clinical Hold For Anti-NGF Class

Oct 17 2016

Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches

Sep 15 2016

Teva Appoints New Global Generics Head Amid Massive Integration

Dec 06 2016

Related Companies

Teva Pharmaceutical Industries Ltd.

Allergan plc

Allergan plc

Allergan plc

Novartis AG

Regeneron Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Additional Topics

Generic Drugs Leadership Business Strategies Commercial BioPharmaceutical

More from Leadership

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window